Cargando…

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis

The Eastern Cooperative Oncology Group consensus guidelines from 2016 recommend interruption of targeted therapy with BRAF- and MEK-inhibitors during radiotherapy with data being based mostly on BRAF monotherapy. The aim of this study is to provide data on the safety of concurrent radiotherapy and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziegler, Johanna S., Kroeze, Stephanie, Hilbers, Marie-Luise, Imhof, Laurence, Guckenberger, Matthias, Levesque, Mitchell P., Dummer, Reinhard, Cheng, Phil, Mangana, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Articles: Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643789/ https://www.ncbi.nlm.nih.gov/pubmed/32658050 http://dx.doi.org/10.1097/CMR.0000000000000682

Ejemplares similares

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2021)

Addendum: Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2022)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: Melanoma brain metastases prognostic score
por: Schaule, Jana, et al.
Publicado: (2020)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: Melanoma brain metastases prognostic score
por: Schaule, Jana, et al.
Publicado: (2020)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
por: Kraehenbuehl, Lukas, et al.
Publicado: (2023)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
por: Mangana, Joanna, et al.
Publicado: (2017)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread
por: Ma, Qiaoli, et al.
Publicado: (2018)

The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2017)

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2018)

Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition
por: Burgermeister, Simon, et al.
Publicado: (2022)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma
por: Tusup, Marina, et al.
Publicado: (2021)

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
por: Zila, Nina, et al.
Publicado: (2018)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages
por: Huber, Roman, et al.
Publicado: (2016)

The A to I editing landscape in melanoma and its relation to clinical outcome
por: Amweg, Austeja, et al.
Publicado: (2022)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
por: Mangana, Joanna, et al.
Publicado: (2022)

Correction: Tusup et al. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA 2021, 7, 5
por: Tusup, Marina, et al.
Publicado: (2022)

Evolving impact of long-term survival results on metastatic melanoma treatment
por: Michielin, Olivier, et al.
Publicado: (2020)

Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
por: Diener, Johanna, et al.
Publicado: (2021)

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_unr089ujvek2bp4eejovl828vm